Structure (GPCR) news
Recent news
Structure Therapeutics Inc: H.C. Wainwright cuts target price to $70 from $100
On June 11, 2026, H.C. Wainwright revised its price target for Structure Therapeutics Inc. (NASDAQ:GPCR), lowering it to $70 from a previous $100, while maintaining a Buy rating on the shares. This adjustment reflects a reassessment of the company’s valuation in light of evolving market dynamics…
AInvest Wire · Jun 11, 2026ImportantStructure Therapeutics plunges 45% premarket on new GLP-1 drug data
Structure Therapeutics plunges 45% premarket on new GLP-1 drug data Structure Therapeutics, a small biotech company, has seen its stock prices plunge by 45% in premarket trading after new data on its GLP-1 drug was released. This new data could potentially challenge the dominance of pharmaceutical…
AInvest Wire · Dec 18, 2023Structure's obesity pill could challenge Lilly, Novo, small study suggests
AInvest Wire · Sep 29, 2023ImportantStructure Therapeutics surges 31% on promising early stage obesity drug data
The once-daily drug helped participants reduce up to 4.5 kgs of body weight on average after four weeks of treatment, the company said.
AInvest Wire · Sep 29, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.